Status:
COMPLETED
Efficacy Pilot Study of Triflusal in the Attenuation of Insulin Resistance in Human Obesity
Lead Sponsor:
J. Uriach and Company
Conditions:
Insulin Resistance
Eligibility:
All Genders
35-60 years
Phase:
PHASE2
Brief Summary
To explore the efficacy of triflusal in the attenuation of insulin resistance in human obesity. Triflusal is a salicylate compound approved in several countries as antithrombotic agent (antiplatelet)....
Detailed Description
Double-blind, randomized, cross-over (three periods) with two dose levels of triflusal, placebo-controlled. Interventions: treatment periods Triflusal 600 mg/d, 15 days Triflusal 900 mg/d , 15 days p...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Ages 35 to 60 years old
Exclusion
Key Trial Info
Start Date :
July 1 2002
Trial Type :
INTERVENTIONAL
End Date :
December 1 2004
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00162799
Start Date
July 1 2002
End Date
December 1 2004
Last Update
June 23 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Unitat de Diabetologia, Endocrinologia y Nutrición Hosp Josep Trueta
Girona, Girona, Spain, 17007